Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:22 PM
Ignite Modification Date:
2025-12-24 @ 10:22 PM
NCT ID:
NCT00062335
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed non-small cell lung cancer
* Medically inoperable stage I or II disease
* Stage III disease eligible provided the following are true:
* No supraclavicular node involvement
* No peripherally located lower lobe tumor AND contralateral upper mediastinal node involvement
* No distant metastasis
* No malignant pleural or pericardial effusion
PATIENT CHARACTERISTICS:
Age
* Not specified
Performance status
* WHO 0-2
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Not specified
Cardiovascular
* No prior myocardial infarction
* No prior complete bundle branch block
* No other prior cardiovascular disease resulting in New York Heart Association class III or IV heart disease
* No clinically significant cardiac arrhythmias
* No congestive heart failure
Pulmonary
* FEV\_1 at least 1.2 L OR
* DLCO at least 60%
Other
* No other prior or concurrent malignancy except cured basal cell skin cancer or carcinoma in situ of the cervix
* No intractable or uncontrolled infection
* No psychological, familial, social, or geographical condition that would preclude study compliance and follow-up
* Able to tolerate a course of radiotherapy
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* At least 3 weeks since prior chemotherapy
* No prior anthracyclines
* No concurrent chemotherapy
Endocrine therapy
* Not specified
Radiotherapy
* No prior radiotherapy to the chest area
Surgery
* No prior therapeutic surgery to the chest area
Other
* No other prior therapy to the chest area
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT00062335
Study Brief:
Protocol Section:
NCT00062335